Amishi Shah
Associate Program Director, Medical Oncology · University of Texas M D Anderson Cancer Center
Credentials: · · · · · ·
History
- Present
Medical Oncology · University of Texas M D Anderson Cancer Center
- Present
Hematology/Oncology Fellowship · University of Texas M D Anderson Cancer Center
- 2010–2013
- 2006–2010
Research
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
New England Journal of Medicine · 2021 · 1,483 citations
The Lancet Oncology · 2022 · 274 citations
Nature Medicine · 2020 · 269 citations
52 papers
42 papers
38 papers · 20 as a fellow
37 papers
29 papers · 9 as a fellow
24 papers
21 papers
18 papers
Clinical trials
- 2022–2023
Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma
Principal investigator · Withdrawn · Phase 2
4D pharma plc
- 2019–2027
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center